1. Triple Versus Double Therapy for the Treatment of Severe Infections Caused by Carbapenem-Resistant Enterobacteriaceae: A Systematic Review and Meta-Analysis
   Lei Wang et al, 2020, Frontiers in Pharmacology CrossRef
2. Novel evidence on sepsis-inducing pathogens: from laboratory to bedside
   Sebastian Gatica et al, 2023, Frontiers in Microbiology CrossRef
3. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria
   James M. Kidd et al, 2018, Expert Opinion on Pharmacotherapy CrossRef
4. Evaluation of the Therapeutic Outcomes of Antibiotic Regimen Against Carbapenemase-Producing Klebsiella pneumoniae: A Systematic Review and Meta-Analysis
   Clement Yaw Effah et al, 2021, Frontiers in Pharmacology CrossRef
5. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli
   Mei Zeng et al, 2023, Journal of Microbiology, Immunology and Infection CrossRef
6. An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients
   Milo Gatti et al, 2022, Expert Review of Anti-infective Therapy CrossRef
7. The role of carbapenem-resistant pathogens in cSSTI and how to manage them
   Paola Del Giacomo et al, 2019, Current Opinion in Infectious Diseases CrossRef
8. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
   Mical Paul et al, 2022, Clinical Microbiology and Infection CrossRef
9. Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant Klebsiella pneumoniae
   Pınar Aysert-Yildiz et al, 2023, Journal of Chemotherapy CrossRef
10. In Vitro Antimicrobial Susceptibility Differences Between Carbapenem-Resistant KPC-2-Producing and NDM-1-Producing Klebsiella pneumoniae in a Teaching Hospital in Northeast China
    Lin Lin et al, 2020, Microbial Drug Resistance CrossRef
11. Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre
    G. Spoletini et al, 2018, Pulmonary Pharmacology & Therapeutics CrossRef
12. Clinical Value Of Intravenous Fosfomycin Combinations
    Tugba SARI et al, 2023, İzmir Tıp Fakültesi Dergisi CrossRef
13. Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections
    Mario Tumbarello et al, 2018, Current Opinion in Infectious Diseases CrossRef
14. Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections (a meta-analysis dataset)
    Akosua A. Agyeman et al, 2020, Data in Brief CrossRef
15. INFEKTIONSKRANKHEITEN
    N. Jung et al, 2020, Rationelle Diagnostik und Therapie in der Inneren Medizin CrossRef
16. Carbapenemase Of Intestinal Rods – The Beginning Of Post-Antibiotic Era?
    Sylwia Joanna Chmielewska et al, 2019, Postępy Mikrobiologii - Advancements of Microbiology CrossRef